Compare Moderna, Inc. (MRNA) vs Stitch Fix Inc (SFIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Stitch Fix Inc — how do they compare? Moderna, Inc. trades at $196.71 (market cap $78.44B), while Stitch Fix Inc trades at $2.74 (market cap $365.41M). The key difference: Moderna, Inc. is far larger — about 214.7× Stitch Fix Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Stitch Fix Inc for 31 Days on average.
| MRNA | SFIX | |
|---|---|---|
Market Cap | $78.44B | $365.41M |
Volume | 14,597,511 | 3,317,935 |
Sector | Health | Consumer Cyclical |
52-Week High | $203.46 | $5.64 |
52-Week Low | $22.36 | $2.16 |
Typical Hold Time | 59 Days | 31 Days |
Enterprise Value | $74.59B | $261.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 5.09% today, with a bullish technical signal supported by moving averages. Recent inclusion in the Nasdaq-100 index has driven positive momentum, though the stock faces valuation concerns after a 500% rally in 2026. Financially, revenue has declined from $18.9B in 2022 to $1.92B in 2025, with net losses widening to -$2.82B. Earnings have consistently beaten expectations, but profitability metrics remain negative.
Outlook: Near-term upside may be capped by high valuations and profit-taking pressure, but long-term growth potential exists in the oncology pipeline. Key risks include sustained revenue declines, competitive threats, and reliance on pipeline success. Analysts are mixed, with a consensus price target of $115.70 suggesting caution despite bullish technicals.
Stitch Fix (SFIX) trades at $2.73, up 2.25% today, showing recent earnings beats but facing bearish technical signals. The company reported improved financials with narrowing losses (-$28.74M net income in 2025 vs -$129M in 2024) and stable $1.27B revenue, though negative cash flow and weak FY27 guidance weigh on sentiment. Analyst consensus is mixed with 24% Buy ratings but a $3.40 price target suggesting 25% upside.
Outlook remains challenging with ongoing profitability concerns and legal investigations creating headwinds. The stock offers speculative appeal given low P/S ratio and AI-driven growth initiatives, but execution risks and competitive pressures require careful monitoring. Near-term performance hinges on reversing active client declines and achieving sustainable EBITDA positivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →
